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Elena per la Cura e lo studio dei Tumori, Rome, Italy
Merkel cell carcinoma is a rare and aggressive form of skin
cancer of likely neuroendocrine origin which affects mainly white
population in sun-exposed areas. The cell of origin is thought to
be the Merkel cell or skin-pressure receptor. It has the propensity
for dermal-lymphatic invasion, and nodal and haematogenous
spread. The survival is dependent on stage at the time of diagno-
sis. The staging evaluation include CT imaging and recently PET
scan. The optimal treatment of patients with Merkel cell carci-
noma remains debated with recent evidence adding support for
multimodality approach. Surgical excision with or without lymph
node dissection followed by post-operative radiotherapy in stage
II disease, is the standard treatment of non metastatic disease.
The role of adjuvant chemotherapy is still controversial. In
patients with metastatic disease, chemotherapy regimens active
in small cell lung cancer are generally used. The combination of
cyclophosphamide, doxorubicin and vincristine (CAV) has an
overall response rate of 75%, whereas the response rate of etopo-
side in combination with cisplatin or carboplatin is 60%. Experi-
ence with other therapeutic agents, such as tumor necrosis
factor, interferon and octreotide is scanty. Our experience in 17
patients, six of whom treated with chemotherapy for advanced
disease, is in agreement with literature data.
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